“GENDER-BASED ANALYSIS OF ADVERSE EFFECTS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES: A COMPARATIVE ”. Global Science Review 2, no. 1 (March 26, 2025): 418–422. Accessed November 16, 2026. https://global-science-review.com/ojs/index.php/gsr/article/view/238.